Clinical cure · participants with confirmed toenail onychomycosis
Griseofulvin may leads to lower clinical cure compared with terbinafine (low certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Griseofulvin may leads to lower mycological cure compared with terbinafine (low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes clinical cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes mycological cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with terbinafine (moderate certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · participants with confirmed toenail onychomycosis
Azole showed no clear difference in recurrence rate compared with terbinafine (low certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Terbinafine leads to higher clinical cure compared with placebo (high certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Terbinafine leads to higher mycological cure compared with placebo (high certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Terbinafine showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
Terbinafine may leads to lower recurrence rate compared with placebo (low certainty).
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · patients with unprovoked venous thromboembolism
VTE extended prophylaxis showed no clear difference in major bleedingd compared with another VTE extended prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortalitye · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found